Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Serotonylation of Vascular Proteins Important to Contraction

  • Stephanie W. Watts ,

    wattss@msu.edu

    Affiliation Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, United States of America

  • Jessica R. C. Priestley,

    Affiliation Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, United States of America

  • Janice M. Thompson

    Affiliation Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, United States of America

Serotonylation of Vascular Proteins Important to Contraction

  • Stephanie W. Watts, 
  • Jessica R. C. Priestley, 
  • Janice M. Thompson
PLOS
x

Abstract

Background

Serotonin (5-hydroxytryptamine, 5-HT) was named for its source (sero-) and ability to modify smooth muscle tone (tonin). The biological effects of 5-HT are believed to be carried out by stimulation of serotonin receptors at the plasma membrane. Serotonin has recently been shown to be synthesized in vascular smooth muscle and taken up from external sources, placing 5-HT inside the cell. The enzyme transglutaminase uses primary amines such as 5-HT to covalently modify proteins on glutamine residues. We tested the hypothesis that 5-HT is a substrate for transglutaminase in arterial vascular smooth muscle, with protein serotonylation having physiological function.

Methodology/Principal Findings

The model was the rat aorta and cultured aortic smooth muscle cells. Western analysis demonstrated that transglutaminase II was present in vascular tissue, and transglutaminase activity was observed as a cystamine-inhibitable incorporation of the free amine pentylamine-biotin into arterial proteins. Serotonin-biotin was incorporated into α -actin, β-actin, γ-actin, myosin heavy chain and filamin A as shown through tandem mass spectrometry. Using antibodies directed against biotin or 5-HT, immunoprecipitation and immunocytochemistry confirmed serotonylation of smooth muscle α–actin. Importantly, the α-actin-dependent process of arterial isometric contraction to 5-HT was reduced by cystamine.

Conclusions

5-HT covalently modifies proteins integral to contractility and the cytoskeleton. These findings suggest new mechanisms of action for 5-HT in vascular smooth muscle and consideration for intracellular effects of primary amines.

Introduction

The primary amine 5-hydroxytryptamine (5-HT, serotonin) is a hormone which exerts multiple effects in the vasculature, including vasoconstriction, vasodilation, endothelial and smooth muscle cell mitogenesis, and potentiation of contractile and mitogenic effects of vasoactive hormones [1], [2]. Multiple 5-HT receptor families (5-HT1–5-HT7) and subtypes exist, and it is through stimulation of these receptors to which the biological actions of 5-HT have been attributed [3]. Recent evidence suggests that the role of 5-HT in the vasculature is more complex than previously appreciated.

We recently discovered that a serotonergic system exists in systemic arteries [4]. Systemic arteries, including the superior mesenteric artery and thoracic aorta, can synthesize 5-HT, metabolize 5-HT to 5-hydroxyindole acetic acid (5-HIAA), take up and release 5-HT. Thus, there are at least two mechanisms by which 5-HT can be placed inside a cell, the first through synthesis and the second through uptake of circulating 5-HT by the serotonin transporter [5]. The existence of intracellular 5-HT raises the question as to the function of 5-HT inside the cell. Serotonin was recently shown to covalently modify small GTPases in the platelet [6]. In this paper, the enzyme transglutaminase (TG) placed 5-HT on glutamine residues of small GTPases to form a glutamyl-amide bond (serotonylation), resulting in activation of the G protein. The platelet, however, is a cell that is enriched in 5-HT (mM concentration), leading to the question as to whether serotonylation was relevant to a cell in which 5-HT was not highly concentrated. More recently, serotonylation of Rho in the pulmonary artery was demonstrated, but this again is a tissue exposed to and which clears significant concentrations of 5-HT [7], [8].

We hypothesized that 5-HT would covalently modify systemic arterial proteins by acting as a substrate for TG, and that this process was physiologically relevant. Our model was the aorta of the rat as this blood vessel contracts to 5-HT, possesses a complete serotonergic system and the receptor mechanisms of contraction are known [5-HT2A receptor-mediated contraction; 9]. Important to these experiments was synthesis of a biotin-conjugated 5-HT that allowed us to identify and track proteins that were serotonylated. We discovered serotonylation of proteins important to contraction and cell shape, and that this may have physiological significance.

Materials and Methods

Animal use/Ethics Statement

Male Sprague-Dawley rats (250–300 g; Charles River Laboratories, Inc., Portage, MI, USA) were used. Rats were anesthetized with pentobarbital (60 mg kg−1, i.p.) prior to removal of tissues. Procedures that involved animals were performed in accordance with the guidelines of Michigan State University, and approved by the Institutional Animal Use and Care Committee.

Immunohistochemistry

Paraffin-embedded tissue sections were dewaxed, unmasked and taken through a protocol as previously described [4]. Primary antibodies used were: transglutaminase II (TGII; mouse monoclonal TG100, LabVision, Fremont CA, USA), N-epsilon gamma glutamyl lysine (mouse monoclonal, ab424, Abcam, Cambridge, MA, USA). In some experiments, primary antibodies were left out of the experiment, and tissues developed only in the presence of secondary antibody.

Western analysis

Protein isolation and western blotting procedures were performed as previously described [4] using standard SDS-PAGE conditions and blotting proteins to nitrocellulose. Primary antibodies used were TGII (LabVision, Fremont CA, USA), smooth muscle cell α-actin (mouse monoclonal, Ab-2, EMD Biosciences, La Jolla, CA, USA) and 5-HT (AbD Serotec, Raleigh NC, USA). Films were scanned and placed within the figure without gamma modifications using Adobe Photoshop.

Transglutaminase activity

Protein homogenate (50 µg) was placed in transglutaminase reaction buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin and leupeptin, 1 mM sodium orthovanadate, 5 mM calcium chloride) containing pentylamine biotin (BAP; 8 mM) or biotinylated amine (IBL, Hamburg, Germany). For biotinylation of 5-HT, 5-HT hydrochloride (Sigma Germany) and EZ-Link Sulfo-NHS-LC-LC-Biotin (Pierce) were used. Equimolar amounts of serotonin and NHS-LC-LC-Biotin were used with pyridine as solvent. After a period of several hours on a roller mixer, the turbid solution was stored over night. On next morning, solvent was evaporated in a vacuum centrifuge and the residue re-suspended in dimethylformamide (DMF). The coupling of the indole amine to biotin was checked through 5-HT enzyme immunoassay (ELISA) by running the ELISA according to manufacturer instructions (IBL International GmbH, Hamburg, Germany Serotonin ELISA cat. No. RE59121). Instead of Biotin required in the Instructions for Use included in the kit, freshly synthesized biotinylated serotonin in different dilutions was used. The purity was checked greater than 90%. Stock concentration was 1.59 mM.

Amines were incubated in the presence of vehicle or the TGII inhibitor cystamine (0.001–10 mM) at 37°C for one hour. An equal volume of 2× SDS sample buffer was added to stop the reaction and the samples were boiled for 10 minutes. Samples were separated on 10% polyacrylamide gels (Bio Rad CA, USA), and transferred to nitrocellulose. Samples were blocked overnight at 4°C in 4% chick egg ovalbulmin [TBS-0.1% Tween+0.025% NaN3,], washed in TBS-Tween for 20 minutes, and incubated with streptavidin-linked, horseradish peroxidase-conjugated secondary antibody (1∶2000, 1 hr, 4°C GE Healthcare, Piscataway NJ, USA). ECL® reagents (GE Healthcare, Piscataway NJ USA) were used to visualize bands. Films were scanned and placed within the figure without gamma modifications using Adobe Photoshop.

5-HT measurement

At room temperature, dissected and cleaned aorta were placed in 100 µL physiological salt solution [PSS: 103 mM NaCl; 4.7 mM KCl; 1.18 mM KH2PO4; 1.17 mM MgSO4-7H2O; 1.6 mM CaCl2-2H2O; 14.9 mM NaHCO3; 5.5 mM dextrose, and 0.03 mM CaNa2 EDTA]. Tissues were briefly dipped in fresh PSS and placed in tissue buffer (0.05 mM sodium phosphate and 0.03 mM citric acid buffer (pH 2.5) containing 15% methanol]. Tissue samples were frozen in −80°C until assay. Samples were thawed, sonicated for 3 seconds and centrifuged for 30 seconds (10,000 g). Supernatant was collected and transferred to new tubes. Tissue pellets were dissolved in 1.0 M NaOH and assayed for protein (Lowry assay). Concentrations of 5-HIAA and 5-HT in tissue supernatants were determined by isocratic high pressure liquid chromatography (HPLC/ESA; described below).

Cell culture and 5-HT uptake

Aortic cells were derived from explants of thoracic aorta. Cells were fed with DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were plated to P-60 dishes or coverslips for Western and immunocytochemical experiments, respectively. Cells used were between passages 2 and 9 and all explants stained positive for smooth muscle cell α-actin (EMD Biosciences, La Jolla, CA, USA). Cells were starved of serum 24 hours prior to experimentation because serum contains 5-HT (determined by HPLC). Cells were incubated for 1 hour in PSS and (+/−10 µM pargyline, a monoamine oxidase A inhibitor) with vehicle (0.01% DMSO) or fluoxetine (1 µM) prior to addition of 5-HT (10−8–10−5 M) or 5-HT-biotin (0–12.7 µM). Cells were placed on ice, washed with PSS, scraped in tissue (HPLC analyses) or lysis buffer (Western analyses), and centrifuged (14, 000 rpm, 10 minutes). The supernatant was removed for HPLC or Westerns (described above). Protein concentration of supernatant and pellet were measured using the Lowry assay.

HPLC measurement

Samples were thawed, sonicated for 3 seconds and centrifuged for 30 seconds (10,000 g). Supernatant was collected and transferred to new tubes. Tissue pellets were dissolved in 1.0 M NaOH and assayed for protein. Concentrations of 5-HIAA, 5-HTP and 5-HT in tissue supernatants were determined by isocratic high pressure liquid chromatography (HPLC/ESA Systems) using electrochemical detection. An ESA MD-150 C18 column was used at 0.4 V and 0.6–9 ml/min flow rate (mobile phase: 90 mM NaH2PO4, 50 mM citric acid, 1.7 mM 1-octanesulfonic acid, 50 µM EDTA, 10% acetonitrile) as compared to standards run daily. Data are reported as ng amine/ mg protein.

Immunocytochemistry

Cells adherent to cover slips were equilibrated in PSS 30 minutes (+10 µM pargyline) prior to a one hour incubation with 5-HT-biotin (12.7 µM) or 5-HT (10 µM) and vehicle or cystamine (10 mM). Cells were rinsed and fixed in 1 mL acetone (1 minute). Primary antibody used was anti-α-actin, smooth muscle specific (mouse monoclonal, Ab-2, EMD Biosciences, La Jolla CA, USA 1∶100 in PBS) or anti-5-HT (rabbit polyclonal, 8250-0004, AbD Serotec, Raleigh NC, USA). Secondary antibodies used were: DyLight™ 488 streptavidin (1∶2000, Rockland Inc, Gilbertsville, PA, USA) and Cy3-conjugated Affini Pure donkey anti-mouse (1∶1000; IgG, Jackson, West Grove PA, USA) or Cy3-conjugated Affini Pure donkey anti-rabbit (1∶1000; IgG, Jackson, West Grove PA, USA) in PBS. Following rinsing, cover slips were blotted dry and mounted on slides using Prolong Gold medium with DAPI (Invitrogen, Carlsbad, CA, USA). Slides were viewed and photographed on a Nikon TE2000 microscope using MetaMorph ® software (Molecular Devices, Sunnyvale CA, USA; all at 20°C). The light source was an X-Cite 120 fluorescence illumination system (EXFO, Mississauga Ontario, Canada), the camera a cool nap ES monochrome digital camera (Roper Scientific Photometrics, Pleasanton CA, USA). Slides were viewed under a 60× Nikon Plan Apo oil-immersion objective (Nikon Corporation, Toyko, Japan) using non-drying immersion oil, type a, formula code 1248 (Cargille, Cedar Grove, NJ, USA). At this magnification, 1 pixel is equivalent to 0.22 microns. Three Nikon filters were used: UV-2E/C96310M (lot number: C48793), Cy3 HYQ 96323 (lot number: C71280), and B-2E/C96311 (lot number: C57657). Excitation ranges were: UV-2E/C 340–380 nm, Cy5 HYQ 530–560 nm and B-2E/C465–495. Emission ranges were UV-2E/C435–C485, Cy3 HYA 573–648, and B-2E/C515–555 nM. Photograph bit depth was 12 nm. No neutral density filters or dichromic beamsplitters were utilized. The LUT was linear and covered the full range of data. Gamma values were equal to 1. Resolution of the photographs was 696×520 pixels (28.3 pixels/cm). There was no deconvolution, reconstruction, rendering or projection. Images were unaltered when combined into the overlay image.

Cell Viability

Confluent petri dishes of rat aortic smooth muscle cells were rinsed of growth medium and equilibrated in physiological salt solution (PSS) for 30 minutes at 37°C and 5% CO2. Cells were incubated for 1 hour in 10 mM cystamine (Sigma-Aldrich, St. Louis, MO, USA) in PSS at 37°C and 5% CO2. The cystamine solution was gently removed but not rinsed from the dishes. Cells were incubated for 5 minutes with 0.05% trypsin-EDTA (Gibco, Invitrogen, Carlsbad, CA, USA). The cell/trypsin mixture was transferred to a conical tube and neutralized with 1.5 mL DMEM (Gibco, Invitrogen, Carlsbad, CA, USA) per 1 mL trypsin. This was centrifuged at 1400 RPM for 6 minutes. The supernatant was removed and the cell pellet was resuspended in 1 mL DMEM. Equal parts cell suspension and 0.4% trypan blue (Sigma-Aldrich, St. Louis, MO, USA) were mixed immediately before cell viability was ascertained using a Bright Line hemocytometer (Reichert, Buffalo, NY, USA) and Nikon TMS phase-contrast microscope (Nikon, Tokyo, Japan). Cells that took up the blue dye were deemed dead and percent viability was calculated by dividing the number of living cells (non-dye containing) by the total number of cells per square centimeter.

Tandem Mass Spectrometry

Tissue homogenates were taken through a transglutaminase activity assay with and without 5-HT-biotin (12.7 µM). Samples incubated with streptavidin-coated magnetic beads (25 µL, Invitrogen, Carlsbad CA, USA) for 1 hour at room temperature, with tumbling. Samples were magnetized to pull down biotin-labelled proteins and supernatant discarded. The magnetic beads were boiled in 2× SDS loading buffer, and separated on polyacrylamide gels (10%). Bands were excised and taken through tandem mass spectrometry by the proteomics core at Michigan State University. Those bands reported are those that only appeared in 5-HT-biotin-labelled samples.

Immunoprecipitation

Immunoprecipitation was carried out as previously described [9], using primary antibody against smooth muscle cell α-actin [(1 µg/200 µg protein) EMD Biosciences, La Jolla, CA, USA] in a phosphate-buffered saline based buffer. Samples were incubated overnight with protein A/G beads (25 µl/sample, Santa Cruz Biotechnologies, Santa Cruz, CA, USA), washed 3× with a protease-inhibitor rich phosphate buffered saline and then beads spun down. Captured beads were incubated in 2× SDS sample buffer, boiled for 10 minutes, centrifuged and the supernatant loaded onto standard SDS-PAGE gels (10%), at which point standard western protocol was used.

Isometric contraction

Helical strips of endothelial cell-intact strips were mounted in tissue baths for isometric tension recordings using Grass transducers and PowerLab data Acquisitions (Colorado Springs, CO, USA). Strips were placed under optimum resting tension (1500 milligrams) and equilibrated for one hour, with washing, before exposure to compounds. Tissue baths contained warmed (37°C), aerated (95% O2/CO2) PSS. Administration of an initial concentration of 10 µM phenylephrine (PE) was used to test arterial strip viability. All tissues had an intact endothelial cell layer, evidenced by a robust (>50%) relaxation to acetylcholine (1 µM) in tissues contracted with a half-maximum concentration of PE. Tissues were incubated for one hour with vehicle (water) or cystamine (0.1–1 mM) for one hour prior to cumulative addition of 5-HT (10−9–10−5 M) or the non-receptor mediated agonist potassium chloride (KCl, 6–100 mM). Data are reported as the percentage of the initial contraction to PE [9].

Materials

All compounds were purchased from Sigma Chemical Company (St. Louis, MO, USA) unless otherwise noted.

Statistical analyses

All values are reported as means±standard error of the mean for the number of animals or explants (N) indicated. Data were analyzed by ANOVA with repeated test where more than two groups were compared (Graph Pad Prism), or two-tailed t test when two groups were compared. P values smaller than 0.05 were considered significant.

Results

Transglutaminase is present and functional in aortic tissue

Figure 1A shows immunohistochemical localization of TG II to the smooth muscle layers of the media in the aorta (lying between elastin/collagen cables), and, to a lesser extent, localization of the classical protein product of TG, N(ε)-(γ-glutamyl) lysine bonds. Using the same TG antibody, a robust band of the appropriate molecular weight (∼70 kDa) was identified in aortic homogenate (figure 1B). It is unclear whether the bands smaller in size but recognized by the TG antibody are degradative products. Figure 1C demonstrates that the TG present in aortic homogenates is functionally active as proteins readily incorporate the biotin-linked amine donor pentylamine biotin (+BAP), compared to samples that had no amine donor (−BAP). Protein modification was significantly reduced by incubating samples with the TG inhibitor cystamine, observed as a decrease in intensity of bands. Cystamine concentration (1–10 mM) was chosen, as in preliminary experiments a concentration response curve showed 0.001 mM–10 mM to have concentration-dependent inhibition of protein amination, with 1–10 mM cystamine causing maximal inhibition (data not shown).

thumbnail
Figure 1. TG protein and activity are observed in rat aorta.

A. Immunohistochemical localization of TG II and the classical protein product containing an N(ε)-(γ-glutamy)-lysine in band in normal rat thoracic aorta. Arrows point to positive staining that is present in samples incubated with primary antibody (primary) but is lost when the primary antibody is removed from the reaction (no primary). Representative of four (4) separate animals. L = lumen. B. Western analysis demonstrating the presence of TGII in homogenate of the rat aorta (arrow). Each lane represents a different animal. Positive control is the rat liver. C. TG activity assay in homogenate from rat thoracic aorta. Samples were incubated in normal TG buffer (in the absence and presence of the TG substrate BAP (−BAP, +BAP respectively), or TG inhibitor cystamine (10 mM). Representative of N>18.

https://doi.org/10.1371/journal.pone.0005682.g001

Endogenous 5-HT is present in arterial tissue and protein serotonylation is carried out by TGII

Figure 2A (left) demonstrates measurable amounts of 5-HT in freshly dissected rat aorta as detected by HPLC. The monoamine oxidase metabolite of 5-HT, 5-HIAA, was also present. The possibility of endogenous protein being serotonylated is supported by the protein bands recognized by an anti-5-HT antibody in homogenates of normal rat aorta not exposed to pargyline or exogenous 5-HT (figure 2A, right). Figure 2B (left) demonstrates that when 5-HT, in its biotinylated form, was incubated with arterial homogenates, a significant number of proteins were labelled (i.e. serotonylated) in a cystamine (10 mM)-dependent fashion. Removal of calcium from the buffer (cystamine +0 Ca2+) did not further reduce protein serotonylation. When biotin alone was used at an equivalent concentration (12.7 µM), no incorporation of biotin into proteins could be observed (figure 2B, right). A narrow doublet at ∼90 kDa was observed, but this was not cystamine-inhibitable, indicating that this likely represents endogenous biotin.

thumbnail
Figure 2. Endogenous 5-HT and TGII activity exists in rat aorta.

A. Left: HPLC measurement of endogenous 5-HT and 5-HIAA in rat thoracic aorta for the number of animals indicated in parentheses. Bars and vertical lines represent means±SEM. Right: Recognition of proteins by an anti-5-HT antibody in normal rat aortic homogenate not exposed to the monoamine oxidase inhibitor pargyline or exogenous 5-HT. Each lane represents a separate animal, and this represents an N = 8. B. Left: TG activity assay using 5-HT-biotin as substrate in homogenates of rat thoracic aorta. Samples were incubated with or without the TG inhibitor cystamine (10 mM), as well as in the presence of cystamine in zero calcium TG buffer. Representative of N>30 different samples. Right: Lack of biotinylated proteins when biotin alone was used as a substrate in the absence or presence of cystamine. Each lane represents a different animal, representative of N = 8.

https://doi.org/10.1371/journal.pone.0005682.g002

Protein serotonylation is time- and concentration-dependent, 5-HT2A receptor-independent

Serotonylation of proteins was detected as early as 1 minute after addition of 5-HT-biotin (12.7 µM), with 5 bands (∼250–280, 220, 110, 70 and 40 kDa) being serotonylated rapidly and the process maximized by 30 minutes (figure 3A, compared to BAP as a substrate, 8 mM). Protein serotonylation was saturable, and serotonylation of proteins occurred at 5-HT concentrations that circulate in normal conditions (1 hour incubation, figure 3B). Serotonylation of proteins was inhibited by adding an excess of 5-HT (weight/weight) to the reaction mixture (figure 3C, left). The right panel of figure 3C shows densitometry for the 40–42 kDa band in the left figure (arrow) in the absence (control, 0) or presence of excess 5-HT. Serotonylation of any protein was not antagonized by the 5-HT2A receptor antagonist ketanserin (100 nM, not shown).

thumbnail
Figure 3. Protein serotonylation is time- and concentration-dependent in aortic homogenates and can be competed against by excess 5-HT.

A. Time course of protein modification for 5-HT-biotin and BAP as substrates. Representative of N = 3 separate experiments. B. Concentration-response curve for aortic protein serotonylation. Representative of N = 5 separate experiments. C. Left: Ability of weight/weight excess of 5-HT to compete off 5-HT-biotin (12. 7 µM) in a TG reaction. Lower blot demonstrates that protein was loaded equally into all lanes as observed through equal α-actin expression. Right panel shows densitometry for the band at 40–42 kDa protein. Representative of N = 6 separate experiments.

https://doi.org/10.1371/journal.pone.0005682.g003

Serotonylation occurs in whole cells and is important to tissue function

Intact cells were capable of taking up 5-HT, and utilizing 5-HT in TG reactions. Figure 4A shows the results of 5-HT uptake studies in which cultured aortic smooth muscle cells were first incubated with the monoamine oxidase inhibitor pargyline (10 µM) to reduce 5-HT metabolism; 5-HIAA concentrations were near zero (open symbol). Cells were then exposed to increasing concentrations of 5-HT in the absence and presence of the serotonin transporter inhibitor fluoxetine (1 µM). Exogenous 5-HT was highly concentrated by the cells in a transporter-dependent manner. 5-HT-biotin was also taken up by the cells, with resultant concentration-dependent serotonylation of proteins (figure 4B). Serotonylation of some proteins was reduced (using the 3.2 µM 5-HT-biotin concentration, 75 and 40–42 kDa proteins (arrows) by ∼28% as ascertained through densitometry; also compare general density of 6.4 µM concentration+/−fluoxetine) but not abolished by the serotonin transporter inhibitor fluoxetine.

thumbnail
Figure 4. Aortic smooth muscle cells take up 5-HT and 5-HT-biotin; 5-HT-biotin is incorporated into cellular proteins.

A. 5-HT uptake of rat aortic smooth muscle cells in the presence of the serotonin transporter inhibitor fluoxetine (1 µM). 5-HIAA levels were nearly zero, and are thus not visible but are marked on the graph. Data are from N = 6 separate aortic explants. Bars and vertical lines represent means±SEM. B. Serotonylation of cytosolic proteins upon incubation of 5-HT-biotin with rat aortic vascular smooth muscle cells in the presence and absence of the serotonin transporter inhibitor fluoxetine (1 µM); lower blot is α-actin loading control. Representative of cells from 6 different aortic explants.

https://doi.org/10.1371/journal.pone.0005682.g004

Tandem mass spectrometry identifies α-actin as a serotonylated protein

Tandem mass spectrometry was used to identify the major proteins serotonylated. For these experiments, TG reactions were carried out normally in samples with and without 5-HT-biotin and then processed as described for tandem mass spectrometry (Materials and Methods). Five proteins were identified in every run of three different experiments, and those reported were only identified in reactions incubated with 5-HT-biotin. Smooth muscle α-actin (∼42 kDa), β-actin (∼41 kDa), γ-actin (∼41 kDa), myosin heavy chain (∼223 kDa) and the actin-binding protein filamin A (∼281 kDa) were identified as the major serotonylated proteins. The next experiments focused on α-actin.

Use of a streptavidin-linked HRP conjugated secondary antibody in blots of samples immunoprecipitated with smooth muscle α-actin validated that 5-HT-biotin was incorporated into α–actin, a process that was abolished by the TG inhibitor cystamine (figure 5A). Smooth muscle α-actin was present in all samples. The physiological relevance of serotonylation is supported by the abolishment of 5-HT-induced aortic contraction by cystamine in a concentration-dependent manner (figure 5B, top). By contrast, KCl-induced contraction was not abolished but was modestly reduced by cystamine (figure 5B, bottom; % PE contraction: vehicle = 85.8±4.00%; cystamine = 61.9±4.41%, p<0.05). In these same tissues, maximal contraction to PE (10 µM) was reduced by ∼80%.

thumbnail
Figure 5. α-actin is serotonylated in aortic smooth muscle cells and inhibition of TG activity reduces aortic contraction to 5-HT.

A. Immunoprecipitation of smooth muscle α-actin from rat aortic homogenates exposed to 5-HT-biotin in a standard transglutaminase reaction. Blots were developed using a streptavidin secondary (top), or exposed to a primary antibody against α-actin (bottom) and developed using standard horseradish peroxidase secondary antibody. Representative of N = 6 different experiments. B. Effect of vehicle (filled symbol) and cystamine (0.1–1 mM; open symbol) on 5-HT (top) and KCl (bottom)-induced contraction in isolated rat aorta. * indicates statistical difference from vehicle-incubated values. Points and vertical lines represent means±SEM for number of animals in parentheses.

https://doi.org/10.1371/journal.pone.0005682.g005

Two other lines of evidence support protein serotonylation. Figure 6A demonstrates that when cultured aortic smooth muscle cells are exposed to either 5-HT (left) or 5-HT-biotin (right) exogenously, the molecule is incorporated into the cell and colocalizes with smooth muscle α-actin. Presence of the TG inhibitor cystamine reduced the incorporation of 5-HT-biotin into actin, and disrupted α-actin filamentation (observed as loss of straight fibers, Figure 6B). The highest concentration of cystamine used (10 mM, 1 hour incubation in PSS) modestly but significantly reduced the viability of cells as assessed by trypan blue exclusion assay (69.0±3.2%, 2 explants, in duplicate), compared to cells treated with PSS without cystamine (92±2.5%).

thumbnail
Figure 6. 5-HT and 5-HT-biotin localize to α-actin and are incorporated into proteins.

A. Immunocytochemistry of aortic smooth muscle cells incubated with exogenous 5-HT (12.7 µM; left) or 5-HT biotin (12.7 µM; right) and α-actin for 1 hour prior to fixation and visualization using an antirabbit fluorescent secondary (for 5-HT) or streptavidin-conjugated secondary (for 5-HT biotin). Representative of four different aortic explants. B. Effect of cystamine (10 mM) on 5-HT-biotin localization in aortic smooth muscle cells. Representative of four different aortic explants.

https://doi.org/10.1371/journal.pone.0005682.g006

Serotonylation occurs in non-vascular tissues

The final experiments tested whether serotonylation was unique to vascular tissue. We compared incorporation of the same concentration of 5-HT biotin (12.7 µM) into equivalent amounts of total protein isolated from aorta, stomach fundus (non-vascular smooth muscle), intestine (non-vascular smooth muscle and 5-HT synthesizing tissue) and cerebral cortex (non-muscular). Figure 7 demonstrates that all tissues actively incorporated 5-HT-biotin into proteins in a TG-dependent fashion, as cystamine inhibited serotonylation. The proteins serotonylated were not, however, identical, though the actin proteins at ∼40 kDa were clearly present in all smooth muscle-based tissues.

thumbnail
Figure 7. Serotonylation occurs in multiple tissues, smooth muscular and non-smooth muscular.

Serotonylation of proteins from homogenates of rat thoracic aorta, rat stomach fundus, rat small intestine and rat cerebral cortex. The right half of the blot shows inhibition of serotonylation by the TG inhibitor cystamine. Representative of three separate experiments, each using 2 samples from different animals.

https://doi.org/10.1371/journal.pone.0005682.g007

Discussion

The biological effects of 5-HT are diverse and numerous, with 5-HT exerting an effect in every physiological system. The present work reveals a receptor-independent mechanism utilized by 5-HT to modify vascular function, namely uptake of 5-HT and covalent modification of proteins that are involved in contraction. This work is important because of the implication of 5-HT in vascular diseases that include hypertension [systemic and pulmonary; 10], [11] and atherosclerosis [12].

Serotonylated proteins

Confirming other reports, TG was present and functional in arterial tissue, both in homogenates and in aortic smooth muscle cells [13], [14]. Multiple proteins were serotonylated upon incubation with 5-HT-biotin, and this process was independent of 5-HT receptor interaction as inhibition of the receptor primarily expressed and active in the aorta, the 5-HT2A receptor, did not modify protein serotonylation. While other 5-HT receptors are expressed in the aorta, they play a minimal role in contraction, and we have made the assumption that they would also play a minimal role in serotonylation. The proteins identified through mass spectrometry as being serotonylated share the common function of being involved, directly or indirectly, in contractility. It is reasonable to argue that these particular proteins—the actins, filamin A and myosin heavy chain– are serotonylated because they are among the most abundant in a smooth muscle-rich tissue. Chowdhury has demonstrated the association of TG with cellular stress fibers [15], placing all the elements for serotonylation close together. This idea is supported by the comparative blots in the smooth muscle-rich stomach fundus and intestine, in which the pattern of protein serotonylation is generally similar. This contrasts with the cortex. While cytoskeletal proteins such as β and γ actin are likely vital to many cellular functions in cortical tissue, smooth muscle α-actin is not heavily expressed. Other proteins are serotonylated in the cortex, evidenced by the different banding pattern of the TG reaction (figure 7). These findings suggest protein serotonylation is not specific to vascular smooth muscle.

For serotonylation to occur, intracellular 5-HT must exist. Arterial smooth muscle has two sources of 5-HT. First, arteries possess the serotonin transporter (SERT) and are able to take up exogenous 5-HT when it is released from 5-HT rich platelets [5]. Importantly, we presently demonstrated the ability of aortic smooth muscle cells to take up and concentrate 5-HT in a SERT-dependent fashion (figure 4). SERT is important for arterial tissue to take up exogenous 5-HT, but SERT is not solely responsible for uptake of 5-HT into tissues and cells. Arteries from SERT knockout rats continue to take up 5-HT, though in a diminished capacity [16]. Alternative means of 5-HT uptake is also one explanation for the inability of fluoxetine to abolish protein serotonylation in aortic smooth muscle cells (figure 4). Uptake, through multiple sources, is thus one way intracellular 5-HT can be enriched. Second, arteries have the ability to synthesize 5-HT [4]. Thus, both exogenous and endogenous 5-HT could potentially be used in serotonylation.

The presence of protein bands recognized by an antibody against 5-HT in samples that had not been exposed to either pargyline or exogenous 5-HT is important, because it suggests serotonylation of protein occurs in arterial smooth muscle exposed to endogenous 5-HT (internally synthesized or taken up). This is further supported by observations made in cultured smooth muscle. Normal serum, necessary to cellular growth, contains 5-HT (∼100 nM, estimated by HPLC). We routinely observe basal levels of endogenous serotonylation of proteins, and even serum-starving cells for 48 hours does not completely remove all serotonylated protein. Thus, one limitation of our cell experiments is that the anti-5-HT antibody we use cannot distinguish between 5-HT incorporated by incubation with media or our exogenously added 5-HT. One can speculate that because serotonylation may be irreversible, as are other TGII-dependent processes, serotonylation may be a signal for modifying the longevity of a protein in a cell. This idea will have to be investigated further. The important finding here is the ability of living cells to take up 5-HT actively and incorporate this 5-HT into proteins. Previous reports described 5-HT-derivatized proteins in 5-HT-rich platelets [17], [18], and our work demonstrates that serotonylation of proteins can occur in tissues relatively poor in 5-HT.

Focus on α-actin and TG

The ability of 5-HT to associate with actin filaments has been known for over twenty years [19], [20], but this work is the first report to demonstrate direct modification of cytoskeletal/contractile proteins by 5-HT. Several lines of evidence support the association of 5-HT with α-actin, including incorporation of both 5-HT and 5-HT-biotin into α-actin protein, colocalization of 5-HT and 5-HT-biotin with α-actin in living smooth muscle cells and inhibition of 5-HT biotin placement on actin by the TG inhibitor cystamine. Isometric contraction in general and that elicited by 5-HT are α-actin-dependent processes [9]. 5-HT-induced isometric contraction was abolished by cystamine while contraction to KCl was modestly reduced. KCl was used in these experiments as a non-receptor dependent contraction, the mechanism of which is supported by L-type calcium channel activation and Rho Kinase [21], [22]. It was important to demonstrate that cells are functional in the presence of cystamine, and they are as evidenced by continued contraction to KCl. The inhibition of 5-HT-induced contraction by cystamine suggests that transglutaminase activity is crucial to 5-HT-induced contraction, perhaps by influencing serotonylation of proteins critical to contraction. However, given the effects of cystamine on KCl-induced contraction and contraction to a maximal concentration of phenylephrine, cystamine is likely influencing the function of contractile elements independent of the process of serotonylation. For example, TGII can also function as a G protein, named Gh, and thus can serve contractility in a more global manner [23]. We have not been able to obtain TG2 knockout mice to separate out the role of TG in mediating 5-HT vs general agonist-stimulated arterial contractility. TG2 knockout mice are viable, and are suggested to be so by increased activity of TG1.

It is a goal to examine other TG inhibitors in contractility assays, but ones examined other than cystamine have questionable selectivity, and thus results from these experiments are difficult to interpret. Cystamine is not without problems, as trypan blue exclusion experiments suggested that high concentrations (10 mM) reduced cell viability by approximately 24%. Thus, it would be ideal to have additional inhibitors. We have tested dansylcadaverine (also a substrate for TG) as a TG inhibitor, and it abolishes both 5-HT and KCl-induced maximum contraction (data not shown). Dansylcadaverine has been published as a substance that can modify receptor internalization as well as inhibit TG activity [24]. Because of these many potential activities, it is difficult to interpret the results from experiments in which dansylcadaverine is used. High levels of guanosine triphosphate (GTP) have been reported to inhibit TG activity, but high GTP would activate any number of other signalling processes [25]. Small molecular inhibitors of TG are being developed but are not readily available [26], [27]. Thus, tools to continue this work should become available in the near future and will be valuable in addressing many of the important issues addressed here.

TG II, the isoform we observed to be expressed in arteries, is ubiquitous and calcium-dependent [23], [28], [29]. To be fair, we did not test for any of the other isoforms of TG reported [23]. TG, in general, has been implicated in the important vascular events of remodelling and Rho activation [30][35]. Cystamine exerts a largely irreversible inhibition against TG [36]. The functions of TG are themselves considered irreversible and mechanisms that reverse the effects of TG are unknown. Thus, it is presently unclear how the process of serotonylation, as carried out by TG, is regulated. Is serotonylation a terminal event for a protein, or can this be undone? Importantly, mechanisms of regulation for TG activity and expression are known, including the ability of nitric oxide and guanine nucleotides to modify TG function [37][39]. Thus, acute regulation of the serotonylating enzyme are recognized.

Perspectives and Limitations

There are a number of limitations to this study that need to be recognized. First, we used a conduit artery for a majority of this work. We cannot directly apply our findings to how 5-HT, through TG-dependent mechanisms, plays a role in control of total peripheral resistance, an event largely supported by the smaller resistance arteries. Second, it has been difficult to demonstrate acute effects of 5-HT-biotin/5-HT on actin filamentation, structure or dynamics in the culture system given the synthetic nature of the cells. We have also been unable to completely remove endogenous 5-HT in these cells and whole tissues (synthesized). Third, identification of the glutamine residues modified by 5-HT biotin/5-HT would be helpful in ultimately allowing for determination of how serotonylation changes protein function. All proteins that were serotonylated contain a significant number of glutamine residues (actins: ∼20/700 residues; filamin A = 65/2647 residues, myosin heavy chain = 129/1938; rat sequences from NCBI), and thus the different sites and combinations thereof that could be serotonylated are numerous. In a similar vein, there are other 5-HT mediated functions, in addition to directly stimulated contraction, that have yet to be addressed in terms of the role of TG-catalyzed protein serotonylation. These include the ability of 5-HT to act as a mitogen and to potentiate the contractile (and mitogenic) effects of other vasoactive substances. The latter is a particularly important function, as the mechanisms behind contractile potentiation/synergy stimulated by 5-HT are not well understood [40]. There is support for an intracellular process utilizing 5-HT to be important for vascular smooth muscle cell mitogenesis, as pulmonary arterial smooth muscle cells depend on the function of the serotonin transporter for 5-HT-stimulated mitogenesis [41], [42]. Finally, we have focused on α-actin modification by 5-HT, as understanding vascular smooth muscle function is central to our laboratory. We have yet to investigate the effects of serotonylation on the cytoskeletal proteins filamin A, β or γ actin. Filamin A is a large protein (281 kDa) that serves as an anchor for proteins like β and γ actin [43]. The significant serotonylation of these proteins suggests that 5-HT exerts a concerted effect on proteins involved in contraction and the cytoskeleton. Another potential avenue of interest for future work is how 5-HT modifies proteins that can modify 5-HT's biological effects and concentration. These include 5-HT receptors, SERT, and enzymes critical to the synthesis of 5-HT such as tryptophan hydroxylase. An understanding of whether and how 5-HT potentially feeds back to elements necessary to 5-HT signal transduction may provide new insight into the regulation of serotonergic systems.

In summary, these studies present the novel findings of serotonylation of contractile proteins in vascular smooth muscle by the enzyme TG. In particular, the covalent modification of smooth muscle α-actin by 5-HT supports that 5-HT influences arterial contractility in a receptor-independent manner. These findings suggest that primary amines like 5-HT may carry out biological effects in receptor-independent manners, and thus this work potentially extends to numerous other avenues of research.

Acknowledgments

The authors thank Doug Whitten and Curtis Wilkerson of the Proteomics Core of MSU for their expertise in tandem mass spectrometry as well as Joe Leykam and the Macromolecular Structure facility for mass spectrometry and work on 5-HT biotin. The authors also thank Dr. Lothar Salewski [IBL, Hamburg Germany] for undertaking synthesis of biotinylated amines, and Mr. Robert Burnett for his expert technical assistance in HPLC analyses.

Author Contributions

Conceived and designed the experiments: SWW JMT. Performed the experiments: SWW JRP JMT. Analyzed the data: SWW JRP JMT. Contributed reagents/materials/analysis tools: SWW JRP JMT. Wrote the paper: SWW.

References

  1. 1. Kaumann AJ, Levy FO (2006) 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111: 67–76.AJ KaumannFO Levy20065-hydroxytryptamine receptors in the human cardiovascular system.Pharmacol Ther1116776
  2. 2. Villalon CM, Centurion D (2007) Cardiovascular responses produced by 5-hydroxytryptamine: a pharmacological update on receptors/mechanisms involved and therapeutic implications. Naunyn Shmiedebergs Arch Pharmacol 376: 45–63.CM VillalonD. Centurion2007Cardiovascular responses produced by 5-hydroxytryptamine: a pharmacological update on receptors/mechanisms involved and therapeutic implications.Naunyn Shmiedebergs Arch Pharmacol3764563
  3. 3. Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533–554.D. HoyerJP HannonGR Martin2002Molecular, pharmacological and functional diversity of 5-HT receptors.Pharmacol Biochem Behav71533554
  4. 4. Ni W, Geddes TJ, Priestley JR, Szasz T, Kuhn DM, et al. (2008) The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br J Pharmacol 154: 663–674.W. NiTJ GeddesJR PriestleyT. SzaszDM Kuhn2008The existence of a local 5-hydroxytryptaminergic system in peripheral arteries.Br J Pharmacol154663674
  5. 5. Ni W, Thompson JM, Northcott CA, Lookingland K, Watts SW (2004) The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol 43: 770–781.W. NiJM ThompsonCA NorthcottK. LookinglandSW Watts2004The serotonin transporter is present and functional in peripheral arterial smooth muscle.J Cardiovasc Pharmacol43770781
  6. 6. Walther DJ, Peter JU, Winter S, Holtje M, Paulmann N, Grohmann M, et al. (2003) Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115: 851–862.DJ WaltherJU PeterS. WinterM. HoltjeN. PaulmannM. Grohmann2003Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release.Cell115851862
  7. 7. Guilluy C, Rolli-Derkinderen M, Tharaux PL, Melino G, Pacaud P, et al. (2007) Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem 282: 2918–2928.C. GuilluyM. Rolli-DerkinderenPL TharauxG. MelinoP. Pacaud2007Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells.J Biol Chem28229182928
  8. 8. Eddahibit S, Adnot S (2006) The serotonin pathway in pulmonary hypertension. Arch Mal Coeur Vaiss 99: 621–625.S. EddahibitS. Adnot2006The serotonin pathway in pulmonary hypertension.Arch Mal Coeur Vaiss99621625
  9. 9. Ogden K, Thompson JM, Hickner Z, Huang T, Tang DD, et al. (2006) A new signalling paradigm for serotonin: use of Crk-associated substrate in arterial contraction. Am J Physiol Heart Circ Physiol 291: H2857–H2863.K. OgdenJM ThompsonZ. HicknerT. HuangDD Tang2006A new signalling paradigm for serotonin: use of Crk-associated substrate in arterial contraction.Am J Physiol Heart Circ Physiol291H2857H2863
  10. 10. Watts SW (2005) 5-HT in systemic hypertension: foe, friend or fantasy. Clin Sci 108: 399–412.SW Watts20055-HT in systemic hypertension: foe, friend or fantasy.Clin Sci108399412
  11. 11. Dempsie Y, Maclean MR (2008) Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol 155: 455–462.Y. DempsieMR Maclean2008Pulmonary hypertension: therapeutic targets within the serotonin system.Br J Pharmacol155455462
  12. 12. Miyazaki M, Higashi Y, Goto C, Chayama K, Yoshizumi M, et al. (2007) Sarpogrelate hydrochloride, as selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol 49: 221–227.M. MiyazakiY. HigashiC. GotoK. ChayamaM. Yoshizumi2007Sarpogrelate hydrochloride, as selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.J Cardiovasc Pharmacol49221227
  13. 13. Lai TS, Liu Y, Li W, Greenberg CS (2007) Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle and endothelial cells. FASEB J 21: 4131–4143.TS LaiY. LiuW. LiCS Greenberg2007Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle and endothelial cells.FASEB J2141314143
  14. 14. Ou H, Haendeler J, Aebly MR, Kelly LA, Cholewa BC, et al. (2000) Retinoic acid-induced transglutaminase and apoptosis in vascular smooth muscle cells. Circ Res 87: 881–887.H. OuJ. HaendelerMR AeblyLA KellyBC Cholewa2000Retinoic acid-induced transglutaminase and apoptosis in vascular smooth muscle cells.Circ Res87881887
  15. 15. Chowdhury ZA, Barsigian C, Chalupowicz GD, Bach TL, Garcia-Manero G, et al. (1997) Colocalization of tissue transglutaminase and stress fibers in human vascular smooth muscle cells and human umbilical vein endothelial cells. Experimental Cell Res 231: 38–49.ZA ChowdhuryC. BarsigianGD ChalupowiczTL BachG. Garcia-Manero1997Colocalization of tissue transglutaminase and stress fibers in human vascular smooth muscle cells and human umbilical vein endothelial cells.Experimental Cell Res2313849
  16. 16. Linder AE, Ni W, Szasz T, Burnett R, Diaz J, et al. (2008) A serotonergic system in veins: serotonin transporter-independent uptake. J Pharmacol Exp Ther 325: 1031–1038.AE LinderW. NiT. SzaszR. BurnettJ. Diaz2008A serotonergic system in veins: serotonin transporter-independent uptake.J Pharmacol Exp Ther32510311038
  17. 17. Szasz R, Dale GL (2002) Thrombospondin and fibrinogen bind serotoin-derivatized proteins onCOAT-platelets. 100: 2827–2831.R. SzaszGL Dale2002Thrombospondin and fibrinogen bind serotoin-derivatized proteins onCOAT-platelets.10028272831
  18. 18. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, et al. (2002) Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. 415: 175–179.GL DaleP. FrieseP. BatarSF HamiltonGL Reed2002Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface.415175179
  19. 19. Alexander JS, Hechtman HB, Shepro D (1987) Serotonin induced actin polymerization and association with cytoskeletal elements in cultured bovine aortic endothelium. Biochem Biophs Res Comm 143: 152–158.JS AlexanderHB HechtmanD. Shepro1987Serotonin induced actin polymerization and association with cytoskeletal elements in cultured bovine aortic endothelium.Biochem Biophs Res Comm143152158
  20. 20. Small DH, Wurtman RJ (1984) Serotonin binds specifically and saturably to an actin-like protein isolated from rat brain synaptosomes. Proc Natl Acad Sci USA 81: 959–963.DH SmallRJ Wurtman1984Serotonin binds specifically and saturably to an actin-like protein isolated from rat brain synaptosomes.Proc Natl Acad Sci USA81959963
  21. 21. Nguelefack TB, Dimo T, Mbuyo EP, Tan PV, Rakatonirina SV, et al. (2005) Relaxant effects of the neutral extract of the leaves of bidens pilosa Linn on isolated rat vascular smooth muscle. Phytother Res 19: 207–210.TB NguelefackT. DimoEP MbuyoPV TanSV Rakatonirina2005Relaxant effects of the neutral extract of the leaves of bidens pilosa Linn on isolated rat vascular smooth muscle.Phytother Res19207210
  22. 22. Sakurada S, Takuwa N, Sugimoto N, Wang Y, Seto M, et al. (2003) Ca2+-dependent activation of rho and rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res 93: 548–556.S. SakuradaN. TakuwaN. SugimotoY. WangM. Seto2003Ca2+-dependent activation of rho and rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction.Circ Res93548556
  23. 23. Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: Nature's biological glues. Biochem J 368: 377–396.M. GriffinR. CasadioCM Bergamini2002Transglutaminases: Nature's biological glues.Biochem J368377396
  24. 24. Woo CH, Kim TH, Choi JA, Ryu HC, Lee JE, et al. (2006) Inhibition of receptor internalization attenuates the TNFalpha-induced ROSE generation in non-phagocytic cells. Biochem Biophys Res Commun 351: 972–978.CH WooTH KimJA ChoiHC RyuJE Lee2006Inhibition of receptor internalization attenuates the TNFalpha-induced ROSE generation in non-phagocytic cells.Biochem Biophys Res Commun351972978
  25. 25. Begg GE, Carrington L, Stokes PH, Matthews JM, Wouters MA, et al. (2006) Mechanism of allosteric regulation of transglutaminase 2 by GTP. Proc Natl Acad Sci USA 103: 19683–19688.GE BeggL. CarringtonPH StokesJM MatthewsMA Wouters2006Mechanism of allosteric regulation of transglutaminase 2 by GTP.Proc Natl Acad Sci USA1031968319688
  26. 26. Pardin C, Pelletier JN, Lubell WD, Keillor JW (2008) Cinnamoyl inhibitors of tissue transglutaminase. J Org Chem 73: 5766–5775.C. PardinJN PelletierWD LubellJW Keillor2008Cinnamoyl inhibitors of tissue transglutaminase.J Org Chem7357665775
  27. 27. Esposito C, Caputo I, Troncone R (2007) New therapeutic strategies for celiac disease: tissue transglutaminase as a target. Curr Med Chem 14: 2572–2580.C. EspositoI. CaputoR. Troncone2007New therapeutic strategies for celiac disease: tissue transglutaminase as a target.Curr Med Chem1425722580
  28. 28. Iismaa SE, Begg GE, Graham RM (2006) Cross-linking transglutaminases with G protein coupled receptor signalling. Sci STKE 353: pe34.SE IismaaGE BeggRM Graham2006Cross-linking transglutaminases with G protein coupled receptor signalling.Sci STKE353pe34
  29. 29. Kang SK, Yi KS, Kwon NS, Park KH, Kim UH, et al. (2004) Alpha1B-adrenoceptor signaling and cell motility: GTPase function of Gh/transglutaminase 2 inhibits cell migration through interaction with cytoplasmic tail of integrin alpha subunits. J Biol Chem 279: 36593–36600.SK KangKS YiNS KwonKH ParkUH Kim2004Alpha1B-adrenoceptor signaling and cell motility: GTPase function of Gh/transglutaminase 2 inhibits cell migration through interaction with cytoplasmic tail of integrin alpha subunits.J Biol Chem2793659336600
  30. 30. Bakker ENTP, Buus CL, Spann JA, Perree J, Ganga A, et al. (2005) Small artery remodeling depends on tissue-type transglutaminase. Circ Res 96: 119–126.ENTP BakkerCL BuusJA SpannJ. PerreeA. Ganga2005Small artery remodeling depends on tissue-type transglutaminase.Circ Res96119126
  31. 31. Johnson TS, Griffin M, Thomas GL, Skill J, Cox A, et al. (1997) The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 99: 2950–2960.TS JohnsonM. GriffinGL ThomasJ. SkillA. Cox1997The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis.J Clin Invest9929502960
  32. 32. Kim SY (2006) Transglutaminase 2 in inflammation. Front Biosci 11: 3026–3035.SY Kim2006Transglutaminase 2 in inflammation.Front Biosci1130263035
  33. 33. Pistea A, Bakker ENTP, Spaan JA, Hardeman MR, van Rooijen N, et al. (2008) Small artery remodeling and erythrocyte deformability in L-NAME-induced hypertension: role of transglutaminases. J Vasc Res 45: 10–18.A. PisteaENTP BakkerJA SpaanMR HardemanN. van Rooijen2008Small artery remodeling and erythrocyte deformability in L-NAME-induced hypertension: role of transglutaminases.J Vasc Res451018
  34. 34. Siegel M, Khosia C (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115: 232–245.M. SiegelC. Khosia2007Transglutaminase 2 inhibitors and their therapeutic role in disease states.Pharmacol Ther115232245
  35. 35. Gupta M, Greenberg S, Eckman DM, Sane DC (2007) Arterial vimentin is a transglutaminase substrate: a link between vasomotor activity and remodeling? J Vasc Res 44: 339–344.M. GuptaS. GreenbergDM EckmanDC Sane2007Arterial vimentin is a transglutaminase substrate: a link between vasomotor activity and remodeling?J Vasc Res44339344
  36. 36. Jeitner TM, Delikatny EJ, Ahlqvist J, Capper H, Cooper AJL (2005) Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem Pharmacol 69: 961–970.TM JeitnerEJ DelikatnyJ. AhlqvistH. CapperAJL Cooper2005Mechanism for the inhibition of transglutaminase 2 by cystamine.Biochem Pharmacol69961970
  37. 37. Bernassola F, Rossi A, Melino G (1999) Regulation of transglutaminases by nitric oxide. Ann NY Acad Sci 887: 83–91.F. BernassolaA. RossiG. Melino1999Regulation of transglutaminases by nitric oxide.Ann NY Acad Sci8878391
  38. 38. Candi E, Paradisi A, Terrinoni A, Pietroni V, Oddi S, et al. (2004) Transglutaminase 5 is regulated by guanine-adenine nucleotides. Biochem J 381: 313–319.E. CandiA. ParadisiA. TerrinoniV. PietroniS. Oddi2004Transglutaminase 5 is regulated by guanine-adenine nucleotides.Biochem J381313319
  39. 39. Lai TS, Hausladen A, Slaughter TF, Eu JP, Stamler JS, et al. (2001) Calcium regulates S-nitrosylation, denitrosylation and activity of tissue transglutaminase. Biochem 40: 4904–4910.TS LaiA. HausladenTF SlaughterJP EuJS Stamler2001Calcium regulates S-nitrosylation, denitrosylation and activity of tissue transglutaminase.Biochem4049044910
  40. 40. Yildiz O, Smith JR, Purdy RE (1998) Serotonin and vasoconstrictor synergism. Life Sci 62: 1723–1732.O. YildizJR SmithRE Purdy1998Serotonin and vasoconstrictor synergism.Life Sci6217231732
  41. 41. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA (1986) Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci USA 83: 674–678.GM NemecekSR CoughlinDA HandleyMA Moskowitz1986Stimulation of aortic smooth muscle cell mitogenesis by serotonin.Proc Natl Acad Sci USA83674678
  42. 42. Fanburg BL, Lee SL (1997) A new role for an old molecule: serotonin as a mitogen. Am J Physiol 272: L795–L806.BL FanburgSL Lee1997A new role for an old molecule: serotonin as a mitogen.Am J Physiol272L795L806
  43. 43. Popowicz GM, Schleicher M, Noegel AA, Holak TA (2006) Filamins: promiscuous organizers of the cytoskeleton. Trends Biochem Sci 31: 411–419.GM PopowiczM. SchleicherAA NoegelTA Holak2006Filamins: promiscuous organizers of the cytoskeleton.Trends Biochem Sci31411419